Randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease ; volume:24 ; number:1 ; day:15 ; month:4 ; year:2023 ; pages:1-10 ; date:12.2023
BMC primary care ; 24, Heft 1 (15.4.2023), 1-10, 12.2023
- Urheber
-
Peabody, John W.
Ganesan, Divya
Valdenor, Czarlota
Paculdo, David
Schrecker, Joshua
Westerfield, Christopher
Heltsley, Rebecca
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12875-023-02042-4
- URN
-
urn:nbn:de:101:1-2023082721084080145255
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Peabody, John W.
- Ganesan, Divya
- Valdenor, Czarlota
- Paculdo, David
- Schrecker, Joshua
- Westerfield, Christopher
- Heltsley, Rebecca
- SpringerLink (Online service)
Ähnliche Objekte (12)
Drug–Drug, Drug–Disease and Disease–Disease Interactions in COVID-19 with Cardiovascular Diseases (CVDs)
A Review of Daclatasvir Drug–Drug Interactions
Drug–Drug Interactions with Direct Oral Anticoagulants
Extracting drug-drug interactions from biomedical texts
Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions
Lurasidone drug-drug interaction studies: a comprehensive review
Case report: Medical cannabis—warfarin drug-drug interaction
DPDDI: a deep predictor for drug-drug interactions
Pharmacovigilance of Drug–Drug Interactions with Nirmatrelvir/Ritonavir
Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the United States
Evaluating drug-drug interaction information in NDF-RT and DrugBank
A Minimal Information Model for Potential Drug-Drug Interactions
Drug–Drug, Drug–Disease and Disease–Disease Interactions in COVID-19 with Cardiovascular Diseases (CVDs)
A Review of Daclatasvir Drug–Drug Interactions
Drug–Drug Interactions with Direct Oral Anticoagulants
Extracting drug-drug interactions from biomedical texts
Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions
Lurasidone drug-drug interaction studies: a comprehensive review
Case report: Medical cannabis—warfarin drug-drug interaction
DPDDI: a deep predictor for drug-drug interactions
Pharmacovigilance of Drug–Drug Interactions with Nirmatrelvir/Ritonavir
Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the United States
Evaluating drug-drug interaction information in NDF-RT and DrugBank
A Minimal Information Model for Potential Drug-Drug Interactions
Drug–Drug, Drug–Disease and Disease–Disease Interactions in COVID-19 with Cardiovascular Diseases (CVDs)
A Review of Daclatasvir Drug–Drug Interactions
Drug–Drug Interactions with Direct Oral Anticoagulants
Extracting drug-drug interactions from biomedical texts
Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions
Lurasidone drug-drug interaction studies: a comprehensive review
Case report: Medical cannabis—warfarin drug-drug interaction
DPDDI: a deep predictor for drug-drug interactions
Pharmacovigilance of Drug–Drug Interactions with Nirmatrelvir/Ritonavir
Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the United States
Evaluating drug-drug interaction information in NDF-RT and DrugBank